Abbvie Inc.

Wyeth

Arqule, Inc.

Other

Abbott Laboratories Corporation

Abbyie Inc.

Abbvie Bahamas Limited

Kevin R Woller

John T Randolph

John K Pratt

Dachun Liu

Charles W Hutchins

Rolf Wagner

Todd Warren Rockway

David A Betebenner

Douglas K Hutchinson

Allan C Krueger

David A DeGoey

Clarence J Maring

Charles A Flentge

Warren M Kati

Derek Cecil Cole

David S Casebier

William A Carroll

Anthony Frank Kreft

Philip R Kym

Arthur Gomtsyan

Michael E Kort

Bryan K Sorensen

Anil Vasudevan

Jerome F Daanen

Todd M Hansen

Kristine E Frank

Anna M Ericsson

Clara I Villamil

Helmut Mack

Michael J Dart

Michael R Schrimpf

Gregory A Gfesser

Richard F Clark

Michael Michaelides

Kent D Stewart

Tao Li

Huaqing Liu

Marlon D Cowart

Venkat Reddy Mali

George A Doherty

Robert J Altenbach

Zhaozhong Jon Jia

Michael L Friedman

Sachin V Patel

Tammie K Jinkerson

Ryan G Keddy

Mark A Matulenko

Kathy A Sarris

Pamela L Donner

Michael D Tufano

Yi Gao

Christopher E Motter

Seble H Wagaw

Lissa T Nelson

Wenke Li

William Jay Moore

Joseph Raymond Stock

Kristina Martha Kutterer

Dennis Michael Kubrak

Eric A Voight

George Diamantidis

Michael L Curtin

Neil Wishart

Howard Robin Heyman

Biqin C Li

Richard J Perner

David J Calderwood

Marina Pliushchev

Michael M Friedman

Ramzi Farah Sweis

Maria A Argiriadi

Lu Wang

Dawn M George

Qingwei I Zhang

Bruce Clapham

Anurupa Shrestha

Zhiren Xia

Charles William Mann

George S Sheppard

John R Koenig

Lisa A Hasvold

Sridhar Peddi

Anthony F Kreft, Iii

Keith F McDaniel

Kenton L Longenecker

Irene I Drizin

Derek W Nelson

Robert G Schmidt

Adrian Hobson

Robin R Frey

Marc J Scanio

Zhiqin Ji

Michael Morytko

Kerren Kalai Swinger

Jeffrey W Voss

Eric C Breinlinger

Carol K Wada

Kathleen Mortell

Zhiguo Bian

The present invention provides for compounds of formula (I) wherein R, R, R, R, R, and R, are as defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL.

Pyrimidines for degrading Bruton's tyrosine kinase

Disclosed are isoindoline carboxamide, dihydropyrrolopyridine carboxamide, and dihydropyrrolopyrimidine carboxamide compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are isoindoline carboxamide, dihydropyrrolopyridine carboxamide, and dihydropyrrolopyrimidine carboxamide compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed.

NAMPT and ROCK inhibitors

Compounds effective in inhibiting replication of Hepatitis C virus ('HCV') are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R, Z, Z, and n are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Furo-3-carboxamide derivatives and methods of use

The invention provide a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomer and isomer thereof wherein the variable are defined herein. The compound of the invention are useful for treating immunological and oncological conditions.

Tricyclic compounds

Disclosed are 1,3-dihydro-2H-isoindole compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of using the compounds to treat diseases during which NAMPT is expressed, e.g., cancer, metabolic disorders, and inflammatory disorders. Disclosed are 1,3-dihydro-2H-isoindole compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of using the compounds to treat diseases during which ROCK is expressed, e.g., cancer, cardiovascular disorders, and inflammatory disorders.

NAMPT and rock inhibitors

The present invention provides for compounds of formula (I) wherein R, R, A, A, A, A, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

Bromodomain inhibitors

Disclosed herein are modulators of TRPV3 of formula (I) wherein X, X, R, R, R, and n are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

TRPV3 modulators

Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.

NAMPT inhibitors

Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X, L, R, R, G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

TRPV1 antagonists

The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Growing community of inventors

Antioch, IL, United States of America

Kevin R Woller